Targeted next-generation sequencing (NGS) could help clinicians make decisions about treating patients with lower risk myelodysplastic syndrome (MDS), according to a study involving 179 individuals. Investigators used a 27-gene panel for NGS in participants with primary MDS. Among the results:
- At least 1 mutation/variant was seen in 82% of patients.
- Nearly one-fourth had ≥3 mutations/variants.
- 83% of patients died and 15% experienced leukemic transformations over a median follow-up of 30 months.
- ASXL1, SETBP1, and TP53 were found to be risk factors for overall survival, and SRSF2, IDH2, and CSF3R were identified as such for leukemia-free survival.
- 4 in every 10 patients had at least 1 adverse mutation/variant for overall survival.
- 2 in every 10 had at least 1 such mutation/variant for leukemia-free survival.
- The number of mutations/variants did not improve prognostic value.
- Survival impact of adverse mutations was most evident in IPSS-R very low/low risk patients.
Tefferi A, Lasho T, Patnaik M, et al. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. [Published online ahead of print September 5, 2017]. Am J Hematol. doi:10.1002/ajh.24901.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al